WO2006048696A1 - Anti-diabetic herbal formulation comprising glycine max - Google Patents
Anti-diabetic herbal formulation comprising glycine max Download PDFInfo
- Publication number
- WO2006048696A1 WO2006048696A1 PCT/IB2004/003585 IB2004003585W WO2006048696A1 WO 2006048696 A1 WO2006048696 A1 WO 2006048696A1 IB 2004003585 W IB2004003585 W IB 2004003585W WO 2006048696 A1 WO2006048696 A1 WO 2006048696A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- extract
- glycine max
- diabetic
- range
- Prior art date
Links
- 244000068988 Glycine max Species 0.000 title claims abstract description 79
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 79
- 230000003178 anti-diabetic effect Effects 0.000 title claims description 20
- 239000003472 antidiabetic agent Substances 0.000 title claims description 16
- 239000012674 herbal formulation Substances 0.000 title description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 45
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 37
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 32
- 239000000284 extract Substances 0.000 claims abstract description 30
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 26
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 20
- 235000008397 ginger Nutrition 0.000 claims abstract description 20
- 101000767750 Carya illinoinensis Vicilin Car i 2.0101 Proteins 0.000 claims abstract description 17
- 101000767759 Corylus avellana Vicilin Cor a 11.0101 Proteins 0.000 claims abstract description 17
- 101000622316 Juglans regia Vicilin Jug r 2.0101 Proteins 0.000 claims abstract description 17
- 101000767757 Pinus koraiensis Vicilin Pin k 2.0101 Proteins 0.000 claims abstract description 17
- 101000767758 Pistacia vera Vicilin Pis v 3.0101 Proteins 0.000 claims abstract description 17
- 239000001841 zingiber officinale Substances 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 101
- 238000009472 formulation Methods 0.000 claims description 93
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
- 239000008103 glucose Substances 0.000 claims description 22
- 239000008280 blood Substances 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 239000006186 oral dosage form Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 230000005856 abnormality Effects 0.000 claims description 3
- 230000002026 carminative effect Effects 0.000 claims description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 229940069428 antacid Drugs 0.000 claims description 2
- 239000003159 antacid agent Substances 0.000 claims description 2
- 230000001458 anti-acid effect Effects 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 230000005484 gravity Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940123457 Free radical scavenger Drugs 0.000 claims 1
- 230000002141 anti-parasite Effects 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 206010040872 skin infection Diseases 0.000 claims 1
- 235000020712 soy bean extract Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 3
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 34
- 241000700159 Rattus Species 0.000 description 25
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 241000196324 Embryophyta Species 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 235000012754 curcumin Nutrition 0.000 description 13
- 229940109262 curcumin Drugs 0.000 description 13
- 239000004148 curcumin Substances 0.000 description 13
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 13
- 229920002472 Starch Polymers 0.000 description 12
- 235000019698 starch Nutrition 0.000 description 12
- 239000008107 starch Substances 0.000 description 12
- 235000013305 food Nutrition 0.000 description 11
- 239000000341 volatile oil Substances 0.000 description 9
- 235000014375 Curcuma Nutrition 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 235000003392 Curcuma domestica Nutrition 0.000 description 6
- 244000008991 Curcuma longa Species 0.000 description 6
- 102000006395 Globulins Human genes 0.000 description 6
- 108010044091 Globulins Proteins 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 235000013976 turmeric Nutrition 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 244000309464 bull Species 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000012970 cakes Nutrition 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 235000002780 gingerol Nutrition 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002510 pyrogen Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- -1 terpenoid compounds Chemical class 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 241000234299 Zingiberaceae Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000000749 insecticidal effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 239000008513 turmeric extract Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 244000161488 Berberis lycium Species 0.000 description 1
- 235000008130 Berberis lycium Nutrition 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 244000075773 Curcuma heyneana Species 0.000 description 1
- 235000009876 Curcuma heyneana Nutrition 0.000 description 1
- 235000006787 Curcuma sp Nutrition 0.000 description 1
- 244000148650 Curcuma sp Species 0.000 description 1
- 229930153442 Curcuminoid Natural products 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 206010052251 Respiratory tract congestion Diseases 0.000 description 1
- 244000152640 Rhipsalis cassutha Species 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 206010042618 Surgical procedure repeated Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 241000234675 Zingiberales Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 108010019077 beta-Amylase Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 244000079386 endoparasite Species 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000001295 genetical effect Effects 0.000 description 1
- 239000010649 ginger oil Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000000871 hypocholesterolemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002013 molluscicidal effect Effects 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 239000002530 phenolic antioxidant Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000003097 polyterpenes Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000001432 zingiber officinale rosc. oleoresin Substances 0.000 description 1
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 description 1
- 229930001895 zingiberene Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the invention provides a novel herbal preparation comprises of Glycine max active fraction containing 7S globulin protein extract, Curcuma longa and Zingiber officinale Linn. Rhizome extract used in treatment of diabetes. BACKGROUND AND PRIOR ART
- Diabetic mellitus is a chronic condition that is diagnosed by a blood test and requires life long management (American Diabetic association, 2002). The more patients understand about the disease the better they are enabled to make good decisions on its management. Dietary therapy and exercise are critical both in preventing and managing diabetic mellitus and the results of the diabetic prevention program research group indicate that changes in life style reduced the incidence of diabetic by 58% (Knowler et al., 2002). In type 1 diabetic mellitus, where there is an absolute deficiency of insulin replacement forms a major component of treatment.
- insulin release from the pancreas is altered and may also be absolutely deficient in amount, and therefore its replacement also plays a part in management, especially when diabetic mellitus has been present for a long time.
- the disease takes an ever-increasing proportion of national and international health care budgets. It is projected to become one of the world's main disablers within the next 25 years. It is very popularly known in medical history as "silent killer". Regions with greatest potential are Asia and Africa, where diabetes mellitus rates could rise to two to three-folds than the present rates.
- Yet another object of the present invention is to prepare herbal dosage from in the form of tablet for easy consumption.
- the present invention provides an herbal formulation useful in the treatment of herbal dosage form from the soya bean milk used as a anti-diabetic.
- the herbal formulation comprising of Glycine max active fraction containing 7 S globulin fraction extract, Zingiber officinalis (rhizome) and curcumin (a phenolic antioxidant).
- Glycine max (Soya bean) protein varies from light cream to white in colour. It is used as nourishing food. It was shown that it produce a significant improvement in general ability and behavioural pattern.
- Glycine max Family Leguminosae
- Botanical description An annual with erect or climbing stem reach a height of one half to six feet, densely clothed with leaves trifoliate, ovate-lanceolate, inconspicuous, borne on auxiliary racemes, white or purple to red purple, normally self pollinated; pods 3cm long in clusters of 3-5, densely hairy containing 3-4 seeds elliptical with hilum, compressed, yellow, choclate or black.
- Soyabean is a native of south-eastern Asia is considered, on the basis of genetical have originated from slender, prostste plan. Soyabean is an important legume crop in Far East.
- Soyabean ranks high among the leguminous crops of the world. It is grown mainly as a food crop of the world. It is grown mainly as a food crop in China, Japan and other country of East Asia.
- the seeds are consumed green, dry or sprouted, whole or split.
- the green seed are used as vegetable; roasted and salted seeds are used in cakes and candies.
- the seeds are ground in to flour and used for bakery products.
- the fatty oil extracted from the seed is used for the industrial purposes.
- the soya been used as a whole been, or processed as a soya milk, tofu, tempesh, soya sauce.
- the increasing popularly of soya food in mainly used in prevention of chronic diseases continues to be a top priority for scientist around the world.
- soya has conformed that the food containing the soya protein may reduce the risk of coronary heart diseases.
- soya has been increasing interest of soya been as an antioxidant effect (Wealth of India, 1992).
- Phytochemistry Soya been seeds contain protein 29.6-50.3, fat 13.5-24.2, fiber 2.84- 2.67, carbohydrate 14.07-23.88.
- the decorticated bean contains about 12 % polysaccharides. It contains higher % of proteins than many other foodstuffs.
- Chief protein is a globulin, glycinine that accounts for 80-90% of the total protein of the seed.
- soya contains the following nitrogenous substances like adenine; arginine, glycine etc and total non-protein nitrogen varies from 2.8-6.8% of the total nitrogen.
- the average mineral composition of mature soya been is as Fe, K, Zn, I etc. it is a good source of beta amylase. It contains variety of pigments, isoflavones, glycosides etc.
- Curcuma comprising about fifty species, distributed in tropical and subtropical regions of Asia, belongs to the tribe Hedychieae and consists of a rather homogenous group of rhizomatous perennials.
- the taxonomic status of Curcuma heyneana was discussed by Firman et al (1988 Phytochem. 27: 3887-3891) based on essential oil analysis.
- Tomlinson's (1969) work based on the anatomical evidence, which has much relevance in the classification of the order Zingiberales.
- Curcuma longa was used predominantly for endoparasites, internal and external injuries and pregnancy related conditions in ethnic community of Trinidad and Tobago. Curcuma longa is used as dietary intake in Nepal (Eigner and Scholz, / Ethnopharmacol 1999, 67(1): 1-6).
- Essential oils are complex mixtures of odorous and steam- volatile compounds that are deposited in the subcuticular space of glandular hair, cell organelle, idioblasts, excretory cavities and canals or exceptionally in heartwoods. In other words, they are very complex, aromatic, volatile mixture containing many different compounds.
- the constituents of essential oils belong to numerous classes of chemical substances, such as hydrocarbons, alcohols, aldehydes, ketones, acids, esters, oxides and ether (Thappa et al, J. Essent. Oil Res., 1982, 11: 97-103).
- Essential oils largely comprises of terpenoid compounds, which constitute two or more isoprene units. Based on this, terpenoids are mainly classified into four groups viz.
- the essential oil forms the basic raw materials for perfume and flavour making industries. They are also used in the cosmetics and pharmaceutical industries. Many natural essential oils are used in aromatherapy to cure and prevent illness due to their therapeutic properties and also because of their fragrance which can influence human thoughts and emotions. Many of the essential oils are reported to have antimicrobial, insect repellent and insecticidal properties.
- Curcuma exhibits diverse pharmacological activities against cancer and tumorgensis.
- Curcumin inhibited rat liver microsomal delta 5 and delta 6 denaturizes (Shimizu et ah, Lipids 1992, 27(7):509-12). Curcuma contains an active principle(s) other than curcuminoid, which can modify the metabolism of lipid and lipoproteins.
- Curcumin as well as turmeric increase bile flow. Essential oils of turmeric have also been found to increase the bile flow. However, some investigators have found it to be ulcerogenic (Prasad et al. J. Physiol. Pharmocol, 1976, 20, 92).
- Curcumin and turmeric have been shown to protect liver against a variety of toxicants in vitro as well as in vivo. They include carbon tetrachloride, aflatoxin B-I, paracetamol iron, and cyclophosphamide in mouse, rat and duckling. Evidence for the hypocholesterolemic and hypolipidemic activities of curcumin has been provided when it was fed with diet to rats for 7 weeks at the concentration of 0.15% (Rao et al. 1970 /. Nut ⁇ . 100, 1307).
- Ethanolic extract of C. longa has been shown to have hypoglycemic activity in normal as well as alloxan - induced diabeties in rats. They have also isolated a lipopoly saccharide from the root of Curcumin, which is similar to bacterial lipopolysaccharides and is immunostimulant (Inagawa et al. Chem Pharm Bull 1992, 40, 1994). The wound healing property of turmeric was investigated long back and its local application was found to be effective (Gujral et al., /. Ind. Med. Association 22, 2731958). A sum of approximately 26 compounds has been isolated from different Curcuma sp. having high antioxidant activity.
- Curcumin did not produce any toxicity either on single administration or on repeated oral administration over a period of 6 months in rat and monkey at doses up to 800 and 1800-mg/kg day, respectively. Curcumin administered orally to patients suffering from chronic antieri or ureitis (CAU) at a dose of 375 mg three times a day for 12 weeks and all the patients who received curcumin alone improved (LaI et al, Phytother Res 13(4): 318-22, 1999). Zingiber officinale Linn. Family: Zingiberaceae
- Rhizomes An herbaceous rhizomatous perennial, reaching up to 90 cm in height under cultivation. Rhizomes are aromatic, thick lobed, pale yellowish, bearing simple alternate distiches narrow oblong lanceolate leaves. The herb develops several lateral shoots in clumps, which begin to dry when the plant matures. Leaves are long and 2-3 cm broad with sheathing bases, the blade gradually tapering to a point. Inflorescence solitary, lateral, radical, pendiculate oblong-cylindrical spikes. Flowers are rare, rather small, calyx superior, gamosepalous, three toothed; open splitting on one side, and corolla of three-sub equal oblong to lanceolate connate greenish segments.
- Ginger is carminative, pungent, stimulant, used widely for indigestion. It is chiefly used to cure diseases due to morbidity of kapha and vata. Ginger with limejuice and rock salt increases appetite and stimulates the secretion of gastric juices. It is said to be used for chronic bronchitis, cold, chest congestion, and cough, difficulty in breathing, dropsy, sore throat, throat ache, stomachache, vomiting and rheumatism. Zinger forms an important constituent of many pharmacopoeal ayurvedic formulations.
- Ginger has been reported to contain usually 1-3 % of volatile oil, pungent principles, viz. gingerols and shogaols and about 6-8 lipids and others. Ginger oil contains zingiberene and bisaboline as major constituents along with other sesqui and mono terpines. Ginger oleoresin contains mainly the pungent principles gingerols and shogaols as well as zingeberine. Shogaols have recently been found twice as pungent as gingerols. (Kiuchi F, et. al., Chem. Pharm. Bull, 1982, 30, 754; waigner H, et al., Plant drug analysis, springer, 1996, 300; Akhila A and Tewari CROMAP, 1984, 6(3), 143-146).
- Table I Effect of formulation (Fl) Glycine max (soya bean) active fraction containing 7S globulin fraction on alloxan induced diabetic rats.
- Table II Effect of formulation (F2) containing Glycine max (soya bean) active fraction containing 7S globulin fraction with Curcuma longa extract on alloxan induced diabetic rats.
- Table III Effect of formulation (F3) containing Glycine max (soya bean) active fraction containing 7S globulin fraction, Curcuma longa with Zingiber officinalis on alloxan induced diabetic rats.
- Table IV Effect of formulation (F4) with out Glycine max (soya bean) active fraction containing 7S globulin fraction on alloxan induced diabetic rats.
- Table VI Effect of formulation (F3) containing Glycine max (soya bean) active fraction containing 7S globulin fraction, Curcuma longa and Zingiber officinale on Glucose tolerance test in rats.
- formulation (F3) containing Glycine max (soya bean) active fraction containing 7S globulin fraction, Curcuma longa and Zingiber officinale on Glucose tolerance test in rats.
- the present invention provides a novel of the invention of an herbal formulation(s) obtained from decoction of two most potent plants having the property of anti-diabetic and used in treatment of diabetes mellitus as a tablet, injection and as a liquid formulation(s).
- the novelty of the invention is a said herbal formulation having the property of anti-diabetic and used in treatment of diabetic mellitus as a tablet and as a formulation.
- an herbal anti-diabetic synergistic formulation(s) containing extracts of plant in pharmacologically effective form.
- herbal formulation(s) the plants selected from the genus Glycine max (2-5 wt %).
- the 7S globulin fraction of Glycine max seed is another embodiment of the invention.
- the plants selected from the genus selected from the genus
- Curcuma longa (1-3 wt %).
- the plants selected from the genus selected from the genus
- composition as a soft/ hard gelatin capsule of oral dosage forms.
- the extract of Glycine max is of active fraction containing 7 S globulin fraction extracts, Zingiber officinalis and Curcuma longa is of rhizome extracts.
- the formulation having the property of improving the anti-diabetic property and used in treatment of type II diabetes and type I diabetes.
- the formulation is used as anti- oxidant, cooling, oleaginous, astringent, nerves relaxant properties and anti-diabetic property.
- the formulation is use to treat diabetic related diseases, blood purifier, anti-periodic and externally applied sprain and wound.
- the said formulation is used as a tonic.
- the said formulation is use as an anti ⁇ parasitic for many skin affections.
- the said formulation is use as antacid, carminative.
- the said formulation is use as cholerectic action.
- the said formulation is use as anti- arthritis.
- the said formulation further comprises the specific gravity 0.992 - 1.505.
- the formulation further comprises the refractive index of 1.5463 -1. 6914.
- the said formulation further comprises proteins, 80.6 - 90.7%.
- the formulation further comprises Amino acids 1.0 - 19.0%
- the said formulation further comprises the fibre 2.845 - 6.27%.
- the formulation further comprises the phosphorus, 0.69%
- the formulation further comprises fat,
- the formulation further comprises carbohydrates, 14.3 -23.5%.
- the suspension at a dose of 50 to 200 mg/kg did not show any abnormality of general condition in treatment as anti ⁇ diabetic activity.
- the suspension at a dose of 50 to 200 mg/kg on anti-diabetic showed significant and dose dependent activity.
- the suspension at a dose of 50 to 200 mg/kg showed significant and dose dependent antioxidant activity.
- liquid dosage form of Glycine max at a dose of 50- 200 mg/kg showed an 11.91- 26.65% protection in diabetes.
- liquid dosage form of Glycine max at a dose of 50- 200 mg/kg shown a 28.77% glucose tolerance.
- the suspension form of Glycine max at a dose of 50- 200 mg/kg shown a 19.5- 45.53% protection in diabetes dose dependency with the combination of Glycine max with Curcuma longa.
- the suspension form of Glycine max at a dose of 50- 200 mg/kg shown a 29.8- 55.0% protection in diabetes dose dependently with the combination of Glycine max, Curcuma longa with Zingiber officinalis.
- the Glycine max (soya bean) seed fraction containing 7S globulin -like protein can be incorporated into a variety of food products, including, without limitation, butter, cakes, candies, ice cream and mayonnaise- chocolate products, preparation of jaggery, water based brinks such as wines and mineral waters.
- the inventive oil is also suitable for encapsulation in gelatine shells to form soft gels/ capsules. Regardless of the particular form in which the inventive oil is prepared, the daily dosage of the fraction to experimental animals fall within the ranges set forth above. Depending on the concentration of the inventive protein fraction in the above form, the total amount of the food product per serving or encapsulated will also vary the desired therapeutic activity. Examples
- Glycine max (Soya bean) 3wt. % Curcuma longa 1.5wt. %
- the formulation is useful to a anti-diabetic. Accordingly, the investigation deals with the oral dosage form have been described in detail giving the formula of the ingredients along with the method and mode of usage of the standardized formulation.
- Hyperglycemia was induced by a single intraperitoneal injection of 120 mg/kg of alloxan monohydrate in sterile saline. After five days of alloxan injection, the diabetic rats (glucose level >350mg/dl) were separated and divided into different groups of six animals each. Blood samples were collected from the tail vein just prior to and 1 and 3h after Glycine max (soya bean) administration. And same procedure repeated for effect of formulation with and with out Glycine max (soya bean) protein on alloxan- induced rats. (Venkatesh et al, 2003) Effect formulation on glucose tolerance in rats Fasted rats were divided into four groups of six rats each.
- IV F2 (200mg/kg) 372.54 ⁇ 19.08 315.61 ⁇ 16.54 255.99 ⁇ 14.65 C Values are mean ⁇ S.D. for six rats;
- IV F3 (200mg/kg) 365.20 ⁇ 17.99 215.61 ⁇ 15.64* 166.99 ⁇ 13.65 C Values are mean ⁇ S.D. for six rats;
- IV F4 (200mg/kg) 365.24 + 18.02 348.15 ⁇ 16.29 304.29 ⁇ 14.61* Values are mean ⁇ S.D. for six rats;
- F4- Formulation contains Curcuma longa and Zingiber officinale without Soya bean active fraction containing 7S globulin fraction.
- Osadebe PO Okide GB, Akabogu IC. Study on anti diabetic activities of crude methanolic extracts of Lorathus mkranthus (Linn) sourced from five different host trees. J. of Ethanopharmacol.2004; 95(2-3): 133- 138.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a novel herbal preparation comprises of Glycine max active fraction containing 7S globulin protein extract, Curcuma longa and Zingiber officinale Linn. rhizome extract used in treatment of diabetes and diabetic related diseases.
Description
ANTI-DIABETIC HERBAL FORMULATION COMPRISING GLYCINE MAX
FIELD OF THE INVENTION
The invention provides a novel herbal preparation comprises of Glycine max active fraction containing 7S globulin protein extract, Curcuma longa and Zingiber officinale Linn. Rhizome extract used in treatment of diabetes. BACKGROUND AND PRIOR ART
Diabetic mellitus is a chronic condition that is diagnosed by a blood test and requires life long management (American Diabetic association, 2002). The more patients understand about the disease the better they are enabled to make good decisions on its management. Dietary therapy and exercise are critical both in preventing and managing diabetic mellitus and the results of the diabetic prevention program research group indicate that changes in life style reduced the incidence of diabetic by 58% (Knowler et al., 2002). In type 1 diabetic mellitus, where there is an absolute deficiency of insulin replacement forms a major component of treatment. In type 2 diabetic mellitus, insulin release from the pancreas is altered and may also be absolutely deficient in amount, and therefore its replacement also plays a part in management, especially when diabetic mellitus has been present for a long time. As the number of people with diabetes multiply world wide, the disease takes an ever-increasing proportion of national and international health care budgets. It is projected to become one of the world's main disablers within the next 25 years. It is very popularly known in medical history as "silent killer". Regions with greatest potential are Asia and Africa, where diabetes mellitus rates could rise to two to three-folds than the present rates. Apart from currently available therapeutic options, many herbal medicines have been recommended for the treatment of diabetes and diabetic related diseases (Sabu and Kuttan, 2002; Zhang and Tan 2000; Chitra et.al., 1998; Padma et.al., 2000; Osadebe et.al., 2004; Obatomei et.al., 1994; Oojewole and Adewunni 2004). Plant medicines are used throughout the world for a range of diabetic presentations. The development of scientifically validated models of alloxan induced- diabetic is vital to the analysis of the functional consequences of pancreatic damage and to testing the recovery efficacy of potentially therapeutic drugs. The role of medicinal
plants in increasing the secretion of insulin and acting as an anti-diabetic formulation in the form of tablet is still much underestimated. The retrieval hypothesis postulates the alloxan agents disrupt the pancreas function as the effect of alloxan agents diminish over time by the treatment of our present herbal formulation investigation resulted in the reappearance of normal functioning of pancreas. Drugs like glibenclamide, penformin-containing substances which has a stimulant activity on diabetic. Accordingly, studies shown that the herbal formulation having the property of improving the functioning of pancreas by alloxan induced diabetic and used in treatment of diabetic as a tablet and acting as a strong anti-diabetic formulation. OBJECT OF THE INVENTION
The main object of the present invention is to provide a novel herbal combination in dosage form used as a anti-diabetic tablet, injection and formulation. Another objective of the present invention is to prepare herbal dosage form that improves in the treatment of diabetic mellitus.
Yet another object of the present invention is to prepare herbal dosage from in the form of tablet for easy consumption.
SUMMARY OF THE INVENTION
Accordingly the present invention provides an herbal formulation useful in the treatment of herbal dosage form from the soya bean milk used as a anti-diabetic. The herbal formulation comprising of Glycine max active fraction containing 7 S globulin fraction extract, Zingiber officinalis (rhizome) and curcumin (a phenolic antioxidant). Glycine max (Soya bean) protein varies from light cream to white in colour. It is used as nourishing food. It was shown that it produce a significant improvement in general ability and behavioural pattern.
Glycine max Family: Leguminosae
Botanical description: An annual with erect or climbing stem reach a height of one half to six feet, densely clothed with leaves trifoliate, ovate-lanceolate, inconspicuous, borne on auxiliary racemes, white or purple to red purple, normally self pollinated; pods 3cm long in clusters of 3-5, densely hairy containing 3-4 seeds elliptical with hilum, compressed, yellow, choclate or black. Soyabean is a native of south-eastern Asia is considered, on the basis of genetical have
originated from slender, prostste plan. Soyabean is an important legume crop in Far East.
Medicinal uses: Soyabean ranks high among the leguminous crops of the world. It is grown mainly as a food crop of the world. It is grown mainly as a food crop in China, Japan and other country of East Asia. The seeds are consumed green, dry or sprouted, whole or split. The green seed are used as vegetable; roasted and salted seeds are used in cakes and candies. The seeds are ground in to flour and used for bakery products. The fatty oil extracted from the seed is used for the industrial purposes. The soya been used as a whole been, or processed as a soya milk, tofu, tempesh, soya sauce. The increasing popularly of soya food in mainly used in prevention of chronic diseases continues to be a top priority for scientist around the world. Even the FDA has conformed that the food containing the soya protein may reduce the risk of coronary heart diseases. There has been increasing interest of soya been as an antioxidant effect (Wealth of India, 1992). Phytochemistry: Soya been seeds contain protein 29.6-50.3, fat 13.5-24.2, fiber 2.84- 2.67, carbohydrate 14.07-23.88. The decorticated bean contains about 12 % polysaccharides. It contains higher % of proteins than many other foodstuffs. Chief protein is a globulin, glycinine that accounts for 80-90% of the total protein of the seed. Besides the true proteins, it contains the following nitrogenous substances like adenine; arginine, glycine etc and total non-protein nitrogen varies from 2.8-6.8% of the total nitrogen. The average mineral composition of mature soya been is as Fe, K, Zn, I etc. it is a good source of beta amylase. It contains variety of pigments, isoflavones, glycosides etc. Pharmacology: In human metabolism experiments soya been proteins comparable to other pulse protein, biological values digestibility coefficient. Soya been is valued in special diet and as an aid in reliving acidosis. The increasing popularly of soya food in mainly used in prevention of chronic diseases continues to be a top priority for scientist around the world. Even the FDA has conformed that the food containing the soya protein may reduce the risk of coronary heart diseases. Their has been increasing interest of soya been as an antioxidant effect and the particular the isoflavones. (Wealth of India, 1992)
CURCUMA LONGA Family: Zingiberaceae
Botanical description: The genus Curcuma comprising about fifty species, distributed in tropical and subtropical regions of Asia, belongs to the tribe Hedychieae and consists of a rather homogenous group of rhizomatous perennials. Govindarajan (1980 Food Science and Nutrition, 14: 119-301 and 1982 Food Science and Nutrition, 17:1-258) published critical reviews on turmeric C. longa. The taxonomic status of Curcuma heyneana was discussed by Firman et al (1988 Phytochem. 27: 3887-3891) based on essential oil analysis. Tomlinson's (1969) work based on the anatomical evidence, which has much relevance in the classification of the order Zingiberales.
Medicinal uses: Ethnobotanical details of some of the species of Curcuma has been reviewed and it was found that Curcuma is useful in the treatment of liver disorders and has a promising kind of broad spectrum hepatoprotective agent which is used in Indonesia (Lin et ah, American J. Chin. Med., 1995 23:243-254). Curcuma longa was used predominantly for endoparasites, internal and external injuries and pregnancy related conditions in ethnic community of Trinidad and Tobago. Curcuma longa is used as dietary intake in Nepal (Eigner and Scholz, / Ethnopharmacol 1999, 67(1): 1-6). Phytochemistry: Essential oils are complex mixtures of odorous and steam- volatile compounds that are deposited in the subcuticular space of glandular hair, cell organelle, idioblasts, excretory cavities and canals or exceptionally in heartwoods. In other words, they are very complex, aromatic, volatile mixture containing many different compounds. The constituents of essential oils belong to numerous classes of chemical substances, such as hydrocarbons, alcohols, aldehydes, ketones, acids, esters, oxides and ether (Thappa et al, J. Essent. Oil Res., 1982, 11: 97-103). Essential oils largely comprises of terpenoid compounds, which constitute two or more isoprene units. Based on this, terpenoids are mainly classified into four groups viz. monoterpenes (with 2 isoprene units i.e. 10 carbon atoms) sesquiterpenes (with 15 carbon atoms), diterpenes (with 4 isoprine units i.e. 20 carbon atoms) and polyterpenes (with 5 or more isoprene units). These terpenoid compounds provide aroma and pungency to plants. The essential oil
forms the basic raw materials for perfume and flavour making industries. They are also used in the cosmetics and pharmaceutical industries. Many natural essential oils are used in aromatherapy to cure and prevent illness due to their therapeutic properties and also because of their fragrance which can influence human thoughts and emotions. Many of the essential oils are reported to have antimicrobial, insect repellent and insecticidal properties.
Pharmacological use: The genus Curcuma exhibits diverse pharmacological activities against cancer and tumorgensis. Anto et al, Mutation Res., 1996, 370:127- 131, has reported the anticancer and antitumour properties of Curcuma longa. It was demonstrated that the inhibitory effect of curcumin on DNA and RNA synthesis in cultured HeLa cells. Dietary curcumin may inhibit azoxymethanol (40 M) induced colonic neoplasia in mice (Huang et al., Cancer Lett 1992, 64(2):117-21). The antimicrobial properties are well known and the result reported by many researchers pointed out the antibiotic activities of Curcuma. Banerjee and Nigam (J. Res. Ind. Med. Yoga Homoeo., 1978, 13: 63-70) reported the antibacterial and antifungal activity of various species of Curcuma. Molluscicidal property of C. longa was reported. The insecticidal property of different species of Curcuma. Curcumin showed anti-inflammatory effect in acute, subacute and chronic models of inflammation in mice and rat models. The oral ED50 in mice, against carrageenin-induced acute oedema was 100.2 mg/kg compared to 78 mg/kg of cortisone. Clinically curcumin did not produce any side effect up to 1600mg/kg/day for 4 weeks in phase-I trials in male volunteers. Phase-II clinical trials have been conducted in patients with rheumatoid arthritis and osteoarthritis. Curcumin inhibited rat liver microsomal delta 5 and delta 6 denaturizes (Shimizu et ah, Lipids 1992, 27(7):509-12). Curcuma contains an active principle(s) other than curcuminoid, which can modify the metabolism of lipid and lipoproteins. Several reports suggest that curcumin as well as turmeric increase bile flow. Essential oils of turmeric have also been found to increase the bile flow. However, some investigators have found it to be ulcerogenic (Prasad et al. J. Physiol. Pharmocol, 1976, 20, 92). The gastric secretion was found to be reduced after 3 h in conscious rabbits by aqueous and methanolic extracts of turmeric (Sakai et al. Chem. Pharm.
Bull. 1989, 37, 215). Curcumin and turmeric have been shown to protect liver against a variety of toxicants in vitro as well as in vivo. They include carbon tetrachloride, aflatoxin B-I, paracetamol iron, and cyclophosphamide in mouse, rat and duckling. Evidence for the hypocholesterolemic and hypolipidemic activities of curcumin has been provided when it was fed with diet to rats for 7 weeks at the concentration of 0.15% (Rao et al. 1970 /. Nutή. 100, 1307). Ethanolic extract of C. longa has been shown to have hypoglycemic activity in normal as well as alloxan - induced diabeties in rats. They have also isolated a lipopoly saccharide from the root of Curcumin, which is similar to bacterial lipopolysaccharides and is immunostimulant (Inagawa et al. Chem Pharm Bull 1992, 40, 1994). The wound healing property of turmeric was investigated long back and its local application was found to be effective (Gujral et al., /. Ind. Med. Association 22, 2731958). A sum of approximately 26 compounds has been isolated from different Curcuma sp. having high antioxidant activity. Curcumin did not produce any toxicity either on single administration or on repeated oral administration over a period of 6 months in rat and monkey at doses up to 800 and 1800-mg/kg day, respectively. Curcumin administered orally to patients suffering from chronic antieri or ureitis (CAU) at a dose of 375 mg three times a day for 12 weeks and all the patients who received curcumin alone improved (LaI et al, Phytother Res 13(4): 318-22, 1999). Zingiber officinale Linn. Family: Zingiberaceae
Botanical description: An herbaceous rhizomatous perennial, reaching up to 90 cm in height under cultivation. Rhizomes are aromatic, thick lobed, pale yellowish, bearing simple alternate distiches narrow oblong lanceolate leaves. The herb develops several lateral shoots in clumps, which begin to dry when the plant matures. Leaves are long and 2-3 cm broad with sheathing bases, the blade gradually tapering to a point. Inflorescence solitary, lateral, radical, pendiculate oblong-cylindrical spikes. Flowers are rare, rather small, calyx superior, gamosepalous, three toothed; open splitting on one side, and corolla of three-sub equal oblong to lanceolate connate greenish segments. (The Wealth of India, NISCOM, D-23, C.S.I.R., New Delhi 1996).
Medicinal use: Ginger is carminative, pungent, stimulant, used widely for indigestion. It is chiefly used to cure diseases due to morbidity of kapha and vata. Ginger with limejuice and rock salt increases appetite and stimulates the secretion of gastric juices. It is said to be used for chronic bronchitis, cold, chest congestion, and cough, difficulty in breathing, dropsy, sore throat, throat ache, stomachache, vomiting and rheumatism. Zinger forms an important constituent of many pharmacopoeal ayurvedic formulations. (Misra B, Bhavaprakasha Nighantu, 5th ed., 1969, p. 14.; Sharma P, Dravyaguna vigyan, part 2, Chauukhamba Publications 1993, p. 331; Indian medicinal plant, a compendium of 500 sps., Part 5, orient Longman Publication, 1997, p. 431; Nadkarni, Indian Materia Medica, vol. 1, 1993, p. 1308; Yogaratnakra, Chauukhamba Publications 1993, p. 320-330; Bhavaprakasha with Vaidyotina commentary by Misra BS; Chikitsa Prakarana Madhyana Khadana- Chauukhamba Publications 1980, p. 683-701). Phytochemistry: Ginger has been reported to contain usually 1-3 % of volatile oil, pungent principles, viz. gingerols and shogaols and about 6-8 lipids and others. Ginger oil contains zingiberene and bisaboline as major constituents along with other sesqui and mono terpines. Ginger oleoresin contains mainly the pungent principles gingerols and shogaols as well as zingeberine. Shogaols have recently been found twice as pungent as gingerols. (Kiuchi F, et. al., Chem. Pharm. Bull, 1982, 30, 754; waigner H, et al., Plant drug analysis, springer, 1996, 300; Akhila A and Tewari CROMAP, 1984, 6(3), 143-146).
Pharmacology: It is used for common cold, due to pathogenic wind cold, characterized by severe intolerance to cold, slight fever, headache, general ache, congestion and running nose. Antihistaminic activity has been studied in ginger. Zingiber officinale was indicated in allergic conditions in traditional text. However they were following crude methods. Toyoda J, Chem. Abst, 1969, 71, 33425; Yogaratnakra, Chauukhamba Publications 1993, p. 320-330; Bhavaprakasha with Vaidyotina commentary by Misra B. S; Chikitsa Prakarana Madhyana Khanda- Chauukhamba Publications 1980, p. 683-701).
BRIEF DESCRIPTION OF THE TABLES
Table I: Effect of formulation (Fl) Glycine max (soya bean) active fraction containing 7S globulin fraction on alloxan induced diabetic rats. Table II: Effect of formulation (F2) containing Glycine max (soya bean) active fraction containing 7S globulin fraction with Curcuma longa extract on alloxan induced diabetic rats. Table III: Effect of formulation (F3) containing Glycine max (soya bean) active fraction containing 7S globulin fraction, Curcuma longa with Zingiber officinalis on alloxan induced diabetic rats. Table IV: Effect of formulation (F4) with out Glycine max (soya bean) active fraction containing 7S globulin fraction on alloxan induced diabetic rats. Table V: Effect of formulation (F3) containing Glycine max (soya bean) active fraction containing 7S globulin fraction, Curcuma longa, Zingiber officinale on relative mean + SEM organ weights of rats (n=6).
Table VI: Effect of formulation (F3) containing Glycine max (soya bean) active fraction containing 7S globulin fraction, Curcuma longa and Zingiber officinale on Glucose tolerance test in rats. Detailed description of the present invention Accordingly, the present invention provides a novel of the invention of an herbal formulation(s) obtained from decoction of two most potent plants having the property of anti-diabetic and used in treatment of diabetes mellitus as a tablet, injection and as a liquid formulation(s).
In another embodiment of the present invention the novelty of the invention is a said herbal formulation having the property of anti-diabetic and used in treatment of diabetic mellitus as a tablet and as a formulation.
Further, in another embodiment of the invention, an herbal anti-diabetic synergistic formulation(s) containing extracts of plant in pharmacologically effective form. In another embodiment of the invention, herbal formulation(s) the plants selected from the genus Glycine max (2-5 wt %).
In another embodiment of the invention, the 7S globulin fraction of Glycine max seed.
In another embodiment of the invention, the plants selected from the genus
Curcuma longa (1-3 wt %). In another embodiment of the invention, the plants selected from the genus
Zingiber officinale (1-3.5 wt %).
In another embodiment of the invention, the composition as a soft/ hard gelatin capsule of oral dosage forms.
In another embodiment of the invention, the extract of Glycine max is of active fraction containing 7 S globulin fraction extracts, Zingiber officinalis and Curcuma longa is of rhizome extracts.
In another embodiment of the invention, the formulation having the property of improving the anti-diabetic property and used in treatment of type II diabetes and type I diabetes. In another embodiment of the invention, the formulation is used as anti- oxidant, cooling, oleaginous, astringent, nerves relaxant properties and anti-diabetic property.
In another embodiment of the invention, the formulation is use to treat diabetic related diseases, blood purifier, anti-periodic and externally applied sprain and wound.
In another embodiment of the invention, the said formulation is used as a tonic.
In another embodiment of the invention, the said formulation is use as an anti¬ parasitic for many skin affections.
In another embodiment of the invention, the said formulation is use as antacid, carminative.
In another embodiment of the invention, the said formulation is use as cholerectic action.
In another embodiment of the invention, the said formulation is use as anti- arthritis. In another embodiment of the invention, the said formulation further comprises the specific gravity 0.992 - 1.505.
In another embodiment of the invention, the formulation further comprises the refractive index of 1.5463 -1. 6914.
In another embodiment of the invention, the formulation used in cakes and candies. In another embodiment of the invention, the said formulation further comprises proteins, 80.6 - 90.7%.
In another embodiment of the invention, the formulation further comprises Amino acids 1.0 - 19.0%
In another embodiment of the invention, the said formulation further comprises the fibre 2.845 - 6.27%.
In another embodiment of the invention, the formulation further comprises the phosphorus, 0.69%
In another embodiment of the invention, the formulation further comprises fat,
13.5 - 24.2%. In another embodiment of the invention, the formulation further comprises carbohydrates, 14.3 -23.5%.
In another embodiment of the invention, the suspension at a dose of 50 to 200 mg/kg did not show any abnormality of general condition in treatment as anti¬ diabetic activity. In another embodiment of the invention, the suspension at a dose of 50 to 200 mg/kg on anti-diabetic showed significant and dose dependent activity.
In another embodiment of the invention, the suspension at a dose of 50 to 200 mg/kg showed significant and dose dependent antioxidant activity.
In another embodiment of the invention, the liquid dosage form of Glycine max at a dose of 50- 200 mg/kg showed an 11.91- 26.65% protection in diabetes.
In another embodiment of the invention, the liquid dosage form of Glycine max at a dose of 50- 200 mg/kg shown a 28.77% glucose tolerance.
In another embodiment of the invention, the suspension form of Glycine max at a dose of 50- 200 mg/kg shown a 19.5- 45.53% protection in diabetes dose dependency with the combination of Glycine max with Curcuma longa.
In another embodiment of the invention, the suspension form of Glycine max at a dose of 50- 200 mg/kg shown a 29.8- 55.0% protection in diabetes dose dependently with the combination of Glycine max, Curcuma longa with Zingiber officinalis. The invention thus meets the need for a new process in which the optimal proportions of vitamins, amino acids, long chain fatty acids and active therapeutic marker compounds are retained in the product and underlies the efficacy of the compound as anti diabetic. Further in another embodiment of present invention the Glycine max (soya bean) seed fraction containing 7S globulin -like protein (Komatsu and Hiranc, 1991) according to the invention can be incorporated into a variety of food products, including, without limitation, butter, cakes, candies, ice cream and mayonnaise- chocolate products, preparation of jaggery, water based brinks such as wines and mineral waters. The inventive oil is also suitable for encapsulation in gelatine shells to form soft gels/ capsules. Regardless of the particular form in which the inventive oil is prepared, the daily dosage of the fraction to experimental animals fall within the ranges set forth above. Depending on the concentration of the inventive protein fraction in the above form, the total amount of the food product per serving or encapsulated will also vary the desired therapeutic activity. Examples
The invention is further illustrated by the following non-limiting examples. Formulation 1 (Fl)
Glycine max (Soya bean) 3wt. %
Lactose 66.7g Starch 1Og
Water q.s. to make 100 ml
Dry mature seed of Glycine max (Soya bean) are washed in purified distilled water of pyrogen free, and were immersed in hot water (30-60° c) for 2-3 hr. the seeds released 7 S globulin were used along with the extract that obtained after squeezed in a silicon cloth to get a white exudates.
Mix the plant constituents and filter the solution and add specified quantity of starch and heat until the starch dissolves and then cool and make up the volume with required amount of water to make 100 ml.
The formulation is useful to a anti-diabetic. Accordingly, the investigation deals with the oral dosage form have been described in detail giving the formula of the ingredients along with the method and mode of usage of the standardized formulation. Formulation 2 (F2)
Glycine max (Soya bean) 3wt. % Curcuma longa 1.5wt. %
Lactose 2.5%
Starch 0.5%
Water q.s. to make 100 ml
Dry mature seed of Glycine max (Soya bean) are washed in purified distilled water of pyrogen free, and were immersed in hot water (30-60° c) for 2-3 hr. the seeds released 7 S globulin were used along with the extract that obtained after squeezed in a silicon cloth to get a white exudates. The Curcuma longa were collected and dried in shade. The dried material (IKg) is then powdered and extracted with water for 5 days. At the end of this, the solvent is decanted and filtered if necessary to remove the plant debris. The extract is then concentrated under vacuum at less than 50 0C. Then the extract is lyophilized to obtain the extract in powder form.
Mix the plant extracts and dissolve them water, filter the solution and add specified quantity of starch and heat the until the starch dissolves and then cool and make up the volume with required amount of water to make 100 ml. The formulation is useful to a anti-diabetic. Accordingly, the investigation deals with the oral dosage form have been described in detail giving the formula of the ingredients along with the method and mode of usage of the standardized formulation.
Formulation 3 (F3)
Glycine max (Soya bean) 3wt. %
Curcuma longa 1.5 %
Zingiber officinale ' 1.5% Lactose 45.7g
Starch 1Og
Water q.s. to make 100 ml
Dry mature seed of Glycine max (Soya bean) are washed in purified distilled water of pyrogen free, and were immersed in hot water (30-60° c) for 2-3 hr. the seeds released 7 S globulin were used along with the extract that obtained after squeezed in a silicon cloth to get a white exudates. The Curcuma longa and Zingiber officinale were collected and dried in shade. The dried material (IKg) is then powdered and extracted with water for 5 days. At the end of this, the solvent is decanted and filtered if necessary to remove the plant debris. The extract is then concentrated under vacuum at less than 500C. Then the extract is lyophilized to obtain the extract in powder form.
Mix the plant extracts and dissolve them water, filter the solution and add specified quantity of starch and heat the until the starch dissolves and then cool and make up the volume with required amount of water to make 100 ml. The formulation is useful to a anti-diabetic. Accordingly, the investigation deals with the oral dosage form have been described in detail giving the formula of the ingredients along with the method and mode of usage of the standardized formulation. Formulation 4 (F4) Curcuma longa 1.5 %
Zingiber officinale 2.5%
Lactose 2Og
Starch 1Og
Water q.s. to make 100 ml The Curcuma longa and Zingiber officinale were collected and dried in shade. The dried material (IKg) is then powdered and extracted with water for 5 days. At the
end of this, the solvent is decanted and filtered if necessary to remove the plant debris. The extract is then concentrated under vacuum at less than 5O0C. Then the extract is lyophilized to obtain the extract in powder form. Mix the plant extracts and dissolve them water, filter the solution and add specified quantity of starch and heat the until the starch dissolves and then cool and make up the volume with required amount of water to make 100 ml.
The formulation is useful to a anti-diabetic. Accordingly, the investigation deals with the oral dosage form have been described in detail giving the formula of the ingredients along with the method and mode of usage of the standardized formulation.
Alloxan-induced hyperglycemia
Hyperglycemia was induced by a single intraperitoneal injection of 120 mg/kg of alloxan monohydrate in sterile saline. After five days of alloxan injection, the diabetic rats (glucose level >350mg/dl) were separated and divided into different groups of six animals each. Blood samples were collected from the tail vein just prior to and 1 and 3h after Glycine max (soya bean) administration. And same procedure repeated for effect of formulation with and with out Glycine max (soya bean) protein on alloxan- induced rats. (Venkatesh et al, 2003) Effect formulation on glucose tolerance in rats Fasted rats were divided into four groups of six rats each. Groups of rats were treated with the formulation and after 30 min of the rats of all groups were orally treated 2g/kg of glucose. Blood samples were collected from the tail vein just prior to glucose administration and at 30 and 90 min after glucose loading. Serum was separated and blood glucose levels were measured immediately by glucose oxidase method. (Venkatesh et al, 2003)
Table I:
Group Experiment Blood glucose (mg/ 100ml)
Basal value Ih 3h
I Diabetic control 355.08 + 18.66 348.42 ± 20.91 342.02 ± 21.16 (distilled water)
II Fl (50mg/kg) 346.08 + 17.11 325.75 + 18.33 309.24 + 19.22
III Fl (100mg/kg) 389.54 + 16.33 340.61 + 17.01 305.99 ± 18.22a
IV Fl (200mg/kg) 392.77 + 13.17 348.61 ± 16.58 288.11 ± 17.44b Values are mean ± S.D. for six rats;
P a < 0.01 and b< 0.001 compared to respective basal value group. Fl- Formulation containing only Glycine max The results of the present study of table-I shows that there is a significant decrease in blood glucose level at 100mg/kg and 200 mg/kg of containing only Glycine max (Soya bean) active fraction containing 7S globulin fraction in alloxan induced diabetes at 3h and percentage protection ranged 11.91-26.65 percentage in controlling the diabetes. Table II:
Group Experiment Blood glucose (mg/100ml)
Basal value Ih 3h
I Diabetic control 345.08 ± 15.66 350.42 ± 22.91 354.02 ± 18.16 (distilled water)
II F2 (50mg/kg) 366.08 ± 15.11 334.75 ± 17.33 306.24 ± 18.22a
III F2 (100mg/kg) 384.08 ± 19.11 337.58 ± 17.01 275.24 ± 16.89b
IV F2 (200mg/kg) 372.54 ± 19.08 315.61 ± 16.54 255.99 ± 14.65C Values are mean ± S.D. for six rats;
Pa< 0.05, b< 0.01 and c< 0.001 compared to respective basal value group. F2- Formulation containing Glycine max (soya bean) active fraction containing 7S globulin fraction with Curcuma longa extract.
The results of the present study of table-II shows that there is a significant decrease in blood glucose level at a dose range 50-100 mg/kg showed significant results and the percentage protection ranged 19.5-45.53 percent in lowering the increased level of blood glucose level. Table III: Group Experiment Blood glucose (mg/ 100ml)
Basal value Ih 3h
I Diabetic control 352.20 ± 21.01 355.60 ± 23.10 353.80 ± 23.80 (distilled water)
II F3 (50mg/kg) 358.30 ± 18.95 342.20± 17.33 251.60 ± 18.22*
III F3 (100mg/kg) 360.10 ± 19.21 330.60 ± 18.91 210.51 ± 15.55*
IV F3 (200mg/kg) 365.20 ± 17.99 215.61 ± 15.64* 166.99 ± 13.65C Values are mean ± S.D. for six rats;
P a< 0.05, b< 0.01 and c< 0.001 compared to respective basal value group.
F3- Formulation containing Glycine max (soya bean) active fraction containing 7S globulin fraction, Curcuma longa with Zingiber officinale
10 The results of the present study of table-Ill shows a significant decrease in blood glucose level at Ih at a dose 200mg/kg and the percentage protection in controlling the increased level of blood glucose were significant at dose range 50- 200mg/kg at 3h and percentage protection ranged 29.8-55.0 percent.
Table IV: Group Experiment Blood glucose (mg/ 100ml)
Basal value Ih 3h
I Diabetic control (distilled 365.08 ± 19.01 358.42 ± 18.35 368.12 ± 20.37 water)
II F4 (50mg/kg) 372.77 ± 15.68 368.61 ± 16.58 348.11 ± 19.54
III F4 (100mg/kg) 358.08 ± 14.35 325.75 ± 16.24 316.24 ± 17.64
IV F4 (200mg/kg) 365.24 + 18.02 348.15 ± 16.29 304.29 ± 14.61* Values are mean ± S.D. for six rats;
P a < 0.01 compared to respective basal value group.
F4- Formulation contains Curcuma longa and Zingiber officinale without Soya bean active fraction containing 7S globulin fraction.
The results of the present study of table-IV showed the probable significant effect
(P<0.05) at 3h at a dose range of 200mg/kg. But the results of table III of formulation F3 is highly significant even when we compared with the percentage protection of that shown 29.8-55.0 percent.
Table V:
F3- Formulation containing Glycine max (soya bean) active fraction containing 7S globulin fraction, Curcuma longa, Zingiber officinale.
Note: No mortality/ gross abnormality were observed in the animals during the treatment of formulation F3.
Table VI:
Group Experiment Blood glucose (mg/ 100ml)
Fasting 30min 90min
I Glucose (2g) 87.08 ± 1.72 165.43 ± 4.98 134.65+ 4.33
II F3 (50mg/kg) 82.06 ± 1.45 145.13 ± 3.75 138.09 ± 2.54
III F3 (100mg/kg) 86.71 ± 1.63 152.54 ± 3.56 125.75±2.76a
IV F3 (200mg/kg) 79.82 ± 2.12 143.51 ± 3.58 102.22 ± 3.65b
Values are mean ± S.D. for six rats;
P a< 0.01 and b< 0.001 compared to respective basal value group. The results showed a significant effect with the formulation F3 containing Glycine max (Soya bean active fraction containing 7S globulin fraction), Curcuma longa and Zingiber officinale at 90 min and the levels were revealed near to the normal values in the scientifically validated model of glucose tolerance test in rats.
References
Agarwal et al., Indian Journal of Experimental Biology, 38, pp994-998, 2000.
Asres K, Indian Drugs, 30,pp 189-190,1993.
Barik et al, Indian Journal of Chemistry, 20B, pp 938-939, 1981. Bean et al, Journal of Natural Product, 48, pp 500, 1985.
Chitra P, Sajithlal GB, Qiandrakasan G. Influence of Aloevera on the healing of dermal wounds in diabetic rats. J. Ethanopharmacol. 1998; 59: 195- 201.
Chopra RN et al, Glossary of Indian Medicinal Plants, 1956.
Chopra RN et al, Indian journal of medical research, 29, pp769, 1941. Chottopadhyay RR, Indian Journal Of Experimental Biology, 31,ρp893, 1993.
Holmann et al, Textbook of Diabetics, ρp467*469, 1991,
Joy KL, Kuttan R, Journal of Ethnopharmacology, 67(2), pp 143, 1999.
Kameshwara Rao et al, manphar vaidhya partika, l,pp 33, 1997.
Kamiya et al, PJiytochemistry, 57, pp 297-301, 2001. Kirthikar KR and Basu BD, Indian Medicinal plants, 1, 1981.
Qbatomi DK, Bikomo EO, Tempje VJ. Anti diabetic properties of the African mistletoe in
STZ induced diabetic rats. J. Ethanopharmacol. 1994; 43(1): 13- 17.
Osadebe PO, Okide GB, Akabogu IC. Study on anti diabetic activities of crude methanolic extracts of Lorathus mkranthus (Linn) sourced from five different host trees. J. of Ethanopharmacol.2004; 95(2-3): 133- 138.
Padma P, Khosa RL, Chansouria JPN. Lipid peroxidation during healing of cutaneous wounds in albino rats. hid. J. of Natural Products.2000; 18(2): 16-19.
Pari L, Journal of Ethnopharmacology, 68(1), pp 321, 1999.
Romesh P, Yuvarajan CR, Journal of Natural Product, 58, ppl242-1243, 1995. Sabu MC, Kuttan R. Anti diabetic activity of medicinal plants and its relationship with their, anti oxidant property. J. Ethanopharmacol.2002; 81(2): 155- 160.
Saraswati Bai N, Bull. Cent. Res. Inst, 3, pp89-107, 1954.
Satake et al, Chem. Pharma Bull, 47, ppl444-1447, 1999.
Setsuko Komatsu and Hisashi Hiranc, Federation of European Biochemical sciences 294(3) 210- 212, 1991.
Singh et al, Indian Journal of Pharmaceutical Sciences, 46, ppl48-149, 1984.
Subramanyan, Current Science,14, pp204, 1945.
Thorpe, Chemurg Dig, 10 (2), ppll, 1951.
Trease and Evan, Textbook of Pharmacognosy, 1983. 35. Trinder P Ann Clinical Biochem 6 pp24-27 1969
Valiathan MS, current science, 75,ppll20-1122, 1988.
Venkatesh et al, Fitoterapia, 74, pp.274-279, 2003.
Venkatesh et, al, Pharmaceutical Biology, 41, 2003.
Zhang XF, Tan B.K.Anti hyperglycaemic and anti oxidant properties of
Androgaphis paniculata 5 in normal and diabetic rats. Clin. Exp. Pharmacol. Physiol.2000;27 (5-
6):358-
363
Claims
1. A formulation comprising an extract of Glycine max in the range of 2-5 wt% along with extract(s) of Curcuma longa in the range of 1-3 wt% and/ or Zingiber officinale in the range of 1-3.5 wt% optionally along with pharmaceutically acceptable carrier(s), said formulation is used in treatment of diabetes and diabetes related diseases.
2. A formulation as claimed in claim 1, wherein the Glycine max extract is seed extract.
3. A formulation as claimed in claim 1, wherein the Glycine extract contains 7S globulin.
4. A formulation as claimed in claim 1, wherein the Zingiber officinalis extract is rhizome extracts.
5. A formulation as claimed in claim 1, wherein said formulation is administered to a subject as soft/ hard gelatin capsule, injection or oral dosage forms.
6. A formulation as claimed in claim 1, wherein the formulation is used in cakes and candies.
7. A formulation as claimed in claim 5, wherein the subject is mammal and preferably human.
8. A formulation as claimed in claim 1, wherein the said formulation having the property of improving the anti-diabetic property and used in treatment of type II diabetes and type I diabetes.
9. A formulation as claimed in claim 1, wherein the formulation is used as a free radical scavenger, anti-oxidant and anti-diabetic.
10. A formulation as claimed in claim 1, wherein the formulation is used to treat diabetic related diseases, as inflammation and wound.
11. A formulation as claimed in claim 1, wherein the formulation is used as anti-parasitic for many skin infections.
12. A f ormulation as claimed in claim 1, wherein the said formulation is used as antacid, carminative.
13. A formulation as claimed in claim 1, wherein the said formulation is used as cholerectic action.
14. A formulation as claimed in claim 1, wherein the said formulation is used as anti-arthritis.
15. A formulation as claimed in claim 1, wherein the said formulation having the specific gravity of 0.992 - 1.505.
16. A formulation as claimed in claim 1, wherein the formulation has a C refractive index of 1.5463 -1. 6914.
17. A formulation as claimed in claim 1, wherein the pharmaceutically acceptable carrier is selected from a group comprising protein, carbohydrate, amino acids, phosphorous, fat and fiber.
18. A formulation as claimed in claim 1, wherein the said ϊormulation further 5 comprises proteins in the range of 80.6 - 90.7 wt %.
19. A formulation as claimed in claim 1, wherein the formulation further comprises amino acids in the range of 1.0 - 19.0 wt %
20. A formulation as claimed in claim 1, wherein the said formulation further comprises the fibre in the range of 2.845 - 6.27 wt % . 0
21. A formulation as claimed in claim 1, wherein the formulation further comprises phosphorus in the range of 0.55 - 0.75 wt %.
22. A formulation as claimed in claim 1, wherein the formulation further comprises fat in the range of 13.5 - 24.2 wt %.
23. A formulation as claimed in claim 1, wherein the formulation further 5 comprises carbohydrates in the range of 14.3 -23.5 wt %.'
24. A use of formulation of claim 1 in the treatment of diabetes and diabetes related diseases.
25. A use as claimed in claim 24, wherein the suspension form of Gtyάne max with Curcuma longa and Zingiber officinalis at a dose of 50- 200 mg/kg 0 reduces the blood glucose level by at least 55.0 % .
26. A use as claimed in claim 24, wherein the said formulation at a dose of 50 to 200mg/kg does not show any abnormality of general condition in mammal preferably human.
27. A use as claimed in claim 24, wherein the said extract of Glycine max at a dose of 50- 200 mg/kg reduces blood glucose level by at least 26.65% in mammal preferably human.
28. A use as claimed in claim 24, wherein the extract of Glycine max at a dose of 50-200 mg/kg show a 28.77% glucose tolerance in mammal preferably human.
29. A use as claimed in claim 24, wherein the extract of Glycine max with Curcuma longa at a dose of 50- 200 mg/kg reduce blood glucose level by at least 45.53% in mammal preferably human.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2004/003585 WO2006048696A1 (en) | 2004-11-03 | 2004-11-03 | Anti-diabetic herbal formulation comprising glycine max |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2004/003585 WO2006048696A1 (en) | 2004-11-03 | 2004-11-03 | Anti-diabetic herbal formulation comprising glycine max |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006048696A1 true WO2006048696A1 (en) | 2006-05-11 |
Family
ID=34959129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2004/003585 WO2006048696A1 (en) | 2004-11-03 | 2004-11-03 | Anti-diabetic herbal formulation comprising glycine max |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2006048696A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1397293A (en) * | 2001-07-23 | 2003-02-19 | 李春澍 | Pumpkin powder |
| US20030035851A1 (en) * | 2001-02-08 | 2003-02-20 | Sophie Chen | Anti-cancer agents and method of use thereof |
| US20030147979A1 (en) * | 2001-10-23 | 2003-08-07 | Tatsumasa Mae | Ligand for peroxisome proliferator-activated receptor |
| US20030185913A1 (en) * | 2002-03-26 | 2003-10-02 | Palpu Pushpangadan | Herbal health protective and promotive nutraceutical formulation for diabetics and process for preparing the same |
-
2004
- 2004-11-03 WO PCT/IB2004/003585 patent/WO2006048696A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030035851A1 (en) * | 2001-02-08 | 2003-02-20 | Sophie Chen | Anti-cancer agents and method of use thereof |
| CN1397293A (en) * | 2001-07-23 | 2003-02-19 | 李春澍 | Pumpkin powder |
| US20030147979A1 (en) * | 2001-10-23 | 2003-08-07 | Tatsumasa Mae | Ligand for peroxisome proliferator-activated receptor |
| US20030185913A1 (en) * | 2002-03-26 | 2003-10-02 | Palpu Pushpangadan | Herbal health protective and promotive nutraceutical formulation for diabetics and process for preparing the same |
Non-Patent Citations (7)
| Title |
|---|
| BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY. FEB 2004, vol. 68, no. 2, February 2004 (2004-02-01), pages 352 - 359, ISSN: 0916-8451 * |
| CROP SCIENCE, vol. 41, no. 6, November 2001 (2001-11-01), pages 1985 - 1987, ISSN: 0011-183X * |
| DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2001 (2001-11-01), STREETER JOHN G: "Simple partial purification of D-pinitol from soybean leaves", XP002335004, Database accession no. PREV200200433075 * |
| DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; February 2004 (2004-02-01), MORIYAMA TATSUYA ET AL: "Soybean beta-conglycinin diet suppresses serum triglyceride levels in normal and genetically obese mice by induction of beta-oxidation, downregulation of fatty acid synthase, and inhibition of triglyceride absorption.", XP002335003, Database accession no. NLM14981298 * |
| DATABASE WPI Section Ch Week 200366, Derwent World Patents Index; Class B04, AN 2003-690274, XP002335035 * |
| EIGNER D ET AL: "Ferula asa-foetida and Curcuma longa in traditional medical treatment and diet in Nepal", JOURNAL OF ETHNOPHARMACOLOGY, vol. 67, no. 1, October 1999 (1999-10-01), pages 1 - 6, XP002335002, ISSN: 0378-8741 * |
| VEDAVANAM K ET AL: "Antioxidant action and potential antidiabetic properties of an isoflevonoid-containing soyabean phytochemical extract spe", PHYTOTHERAPY RESEARCH, JOHN WILEY & SONS LTD. CHICHESTER, GB, vol. 13, no. 7, 1999, pages 601 - 608, XP002973175, ISSN: 0951-418X * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Garcia-Oliveira et al. | Traditional plants from Asteraceae family as potential candidates for functional food industry | |
| Sachan et al. | Medicinal uses of spices used in our traditional culture: Worldwide | |
| Singh et al. | Cuminum cyminum–A popular spice: An updated review | |
| Ratnam et al. | A review on Cucurbita pepo | |
| Ramalingum et al. | The therapeutic potential of medicinal foods | |
| Rathore et al. | Potential health benefits of major seed spices | |
| Manohar et al. | Ethnopharmacology of Lepidium sativum Linn (Brassicaceae): a review | |
| Najjaa et al. | Aromatic and medicinal plants of Tunisian arid and desert zone used in traditional medicine, for drug discovery and biotechnological applications | |
| Baregama et al. | Phytoconstituents, pharmacological activity, and medicinal use of Lepidium sativum Linn.: A review | |
| US20070042062A1 (en) | Novel anti-diabetic herbal formulation | |
| MXPA00012314A (en) | Composition and method for treatment of inflammation and pain in mammals. | |
| Bahrami et al. | Medicinal properties of Daucus carota in traditional Persian medicine and modern phytotherapy | |
| Alamgir | Pharmacopoeia and herbal monograph, the aim and use of WHO’s herbal monograph, WHO’s guide lines for herbal monograph, pharmacognostical research and monographs of organized, unorganized drugs and drugs from animal sources | |
| Shahrajabian et al. | Asafoetida, God's food, a natural medicine | |
| Banik et al. | Phytochemistry, health benefits and toxicological profile of Aloe | |
| Ansari et al. | Therapeutics and pharmacology of Gul-e-Surkh (Rosa damascena Mill): An important Unani drug | |
| Chauhan et al. | Biological actions of Opuntia species. | |
| Sachan et al. | In-vitro & in-vivo efficacy of Moringa oleifera plant constituents in urolithiasis as antilithiatic drug | |
| Aleem et al. | Therapeutic potential of Habb-ul-Aas (Myrtus communis Linn.) with unani perspective and modern pharmacology: A review | |
| Kalam et al. | Therapeutic potential of rhizomatous plants used in Unani medicare system | |
| Kren et al. | Medicinal and aromatic plants-industrial profiles | |
| Koller | Javanese medicinal plants used in rural communities | |
| Sharma et al. | Exploring the potential of giloy vine: Applications and opportunities in the agrofood industry–A comprehensive review | |
| Patil et al. | Role of Indian spices as nutraceutical and therapeutical agents | |
| WO2006048696A1 (en) | Anti-diabetic herbal formulation comprising glycine max |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 1286/DELNP/2005 Country of ref document: IN |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 04798762 Country of ref document: EP Kind code of ref document: A1 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 04798762 Country of ref document: EP Kind code of ref document: A1 |